WPDesigns

Further to the Company’s announcement on 17 October 2017 (‘Collaborative Partnership commences to develop new AI diagnostic tools’), Resonance Health Ltd is pleased to advise that it has developed a new artificial intelligence (AI) tool for the automated review of chest computed tomography (CT) scans of patients with suspected pulmonary embolism (PE).

Resonance Health Ltd is pleased to announce that it has entered into a licence agreement with the Telethon Kids Institute in Perth, Western Australia, and the Erasmus University Medical Centre, in Rotterdam, The Netherlands, for the use of computed tomography (“CT”) datasets that will be used by the Company in the potential development of a

Resonance Health Limited is pleased to announce that it has filed a provisional patent covering the application of novel Antisense Oligonucleotides (ASOs) to treat liver related disease.

Resonance Health is delighted to provide you with our latest customer newsletter, where you can find an update on all our latest acitvities. To read the newsletter please click here

Resonance Health is pleased to announce that it has entered into a Solution Partner Agreement with Siemens Healthcare GmbH (Siemens Healthineers), a leading medical technology company headquartered in Erlangen, Germany, for the distribution of the Company’s FerriSmart product through the Siemens Healthineers Digital Marketplace.

Resonance Health is pleased to announce that it has successfully trained a neural network (artificial intelligence, ‘AI’) for the automated assessment of liver fat from MRI data.

Resonance Health is pleased to announce that it has filed a provisional patent for the discovery and use of novel blood markers to determine an individual’s iron status.  These blood markers have been identified as part of the Company’s molecular medicine R&D program.